Quick answer: peptide patents and FDA exclusivity are two separate shields against generic competition. A patent from the U.S. Patent and Trademark Office generally lasts 20 years from filing, while FDA exclusivity is set by statute: 5 years for a new chemical entity, 3 years for new clinical studies, 7 years for an orphan drug and 12 years for a biologic.[1][4] For the two biggest peptide drugs, the Orange Book lists semaglutide’s compound patent expiring December 5, 2031 and tirzepatide’s on May 13, 2036.[7][8]
This guide explains how the two systems work, why size matters for peptides, and why “research” peptides like BPC-157 sit outside both. For related rules, see our FDA and regulation hub, generic semaglutide and generic tirzepatide.
Patents vs exclusivity: what’s the difference?
FDA explains the distinction this way: patents are property rights that can be obtained at any stage of development, while exclusivity attaches only when FDA approves a drug and blocks or delays approval of competitors.[1] They can overlap, run at different times or cover different things.
| Patent | Regulatory exclusivity | |
|---|---|---|
| Granted by | U.S. Patent and Trademark Office | Arises by law on FDA approval |
| Usual length | 20 years from filing, with possible extension | 3 to 12 years, depending on type |
| Covers | Compound, formulation, method of use, manufacturing | The approved drug, regardless of patents |
| Can be challenged | Yes, in court or at the patent office | No, it runs its set term |
| Published in | Orange Book (drugs) or Purple Book (biologics) | Same |
The main types of exclusivity
New chemical entity (NCE): 5 years. For a drug whose active moiety has never been approved, no generic (ANDA) or 505(b)(2) application can be submitted for 5 years. A generic maker that challenges a patent can file after 4 years.[2]
New clinical investigation: 3 years. When a change to an approved drug, such as a new indication or dose, needed new clinical studies, FDA cannot approve a generic for that change for 3 years.[2]
Orphan drug: 7 years. A drug approved for a rare disease or condition gets 7 years during which FDA generally cannot approve the same drug for the same use.[3]
Pediatric: 6 months. This is added onto existing patents and exclusivities. It does not stand alone.[1]
Biologics: 12 years. Under the Biologics Price Competition and Innovation Act (BPCIA), a biosimilar cannot be approved until 12 years after the reference product was first licensed, and cannot be submitted until 4 years after.[4]
Why the 40-amino-acid line matters for peptides
Whether a peptide gets 5 years or 12 depends on whether it counts as a “protein.” FDA’s regulation defines a protein as an alpha amino acid polymer with a specific, defined sequence “greater than 40 amino acids in size.”[5]
- 40 amino acids or fewer: regulated as a drug under an NDA, listed in the Orange Book, eligible for NCE exclusivity. Semaglutide and tirzepatide fall here.
- More than 40: regulated as a biologic under a BLA, listed in the Purple Book, eligible for 12-year exclusivity.[9]
On March 23, 2020, products such as insulin and human growth hormone that had historically been approved as drugs were “deemed to be” biologic licenses and moved from the Orange Book to the Purple Book.[6]
The line is still being argued. In a case over retatrutide, FDA decided the molecule was a drug, not a protein, because it has fewer than 41 alpha amino acids. On September 30, 2025, a federal court in Indiana agreed it is not a protein but set aside FDA’s reading of when a product is “analogous” to one, and sent the question back to FDA.[10]
Semaglutide and tirzepatide: the real dates
Here is what FDA’s Orange Book listed when we checked in October 2026:
| Drug | Key patent | Orange Book expiry | Exclusivity listed |
|---|---|---|---|
| Semaglutide (Ozempic, NDA 209637) | US 8,129,343 (drug substance and product) | December 5, 2031[7] | Indication exclusivity to January 28, 2028[7] |
| Tirzepatide (Mounjaro, NDA 215866) | US 9,474,780 (drug substance and product) | May 13, 2036[8] | NCE exclusivity to May 13, 2027[8] |
Some secondary sources put U.S. semaglutide compound protection at June 2032. That would be consistent with a 6-month pediatric extension, but the Orange Book entry we checked showed December 5, 2031 with no pediatric exclusivity attached, so treat 2032 as unverified.[7]
The tirzepatide date lines up with the patent term extension cap of 14 years from approval (Mounjaro was approved May 13, 2022). Both drugs also have many later formulation and device patents, so the compound patent date is not necessarily the day generics launch. Patent challenges and settlements can move entry earlier.
Outside the U.S., timelines are different. Novo Nordisk let a key Canadian patent lapse, and Health Canada approved the first generic semaglutide on April 28, 2026.[12] Generics also launched in India in March 2026. See peptide legality by country.
Why research peptides can’t be patented (and why that matters)
A U.S. patent requires novelty: an invention cannot be patented if it was already described in a printed publication or otherwise available to the public before filing.[11] Peptides such as BPC-157, TB-500 and epitalon were described in published research decades ago. Any original compound patents are expired or never existed, so no one can patent the molecule itself today. Narrower patents on a new formulation, delivery method or use may still be possible.
That has a practical effect. Phase 3 trials are expensive, and without a strong patent few companies have a reason to pay for them. But regulatory exclusivity offers a partial answer: an old molecule that has never been approved would still qualify for 5-year NCE exclusivity, or 7-year orphan exclusivity for a rare disease, if a company won approval.[2][3]
What this means for patients
- Brand GLP-1 prices in the U.S. are protected by patents into the 2030s, which is why compounded tirzepatide drew so much attention during the shortages.
- “Generic” peptide products sold online before patent expiry are not approved generics.
- To check a drug yourself, search the Orange Book (drugs) or Purple Book (biologics) by name.[9]
This is general information, not legal advice. Patent dates can change through litigation, extensions or settlements.
